Literature DB >> 26181243

How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy.

Michael D Farwell1, Amy S Clark2, David A Mankoff1.   

Abstract

Mesh:

Substances:

Year:  2015        PMID: 26181243     DOI: 10.1001/jamaoncol.2015.0667

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  5 in total

Review 1.  Development of Companion Diagnostics.

Authors:  David A Mankoff; Christine E Edmonds; Michael D Farwell; Daniel A Pryma
Journal:  Semin Nucl Med       Date:  2016-01       Impact factor: 4.446

Review 2.  Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers.

Authors:  Austin R Pantel; David A Mankoff
Journal:  Cancer Lett       Date:  2016-05-16       Impact factor: 8.679

3.  Evaluation of Cross-Calibrated 68Ge/68Ga Phantoms for Assessing PET/CT Measurement Bias in Oncology Imaging for Single- and Multicenter Trials.

Authors:  Darrin W Byrd; Robert K Doot; Keith C Allberg; Lawrence R MacDonald; Wendy A McDougald; Brian F Elston; Hannah M Linden; Paul E Kinahan
Journal:  Tomography       Date:  2016-12

Review 4.  SPECT and PET radiopharmaceuticals for molecular imaging of apoptosis: from bench to clinic.

Authors:  Xiaobo Wang; Han Feng; Shichao Zhao; Junling Xu; Xinyu Wu; Jing Cui; Ying Zhang; Yuhua Qin; Zhiguo Liu; Tang Gao; Yongju Gao; Wenbin Zeng
Journal:  Oncotarget       Date:  2017-03-21

5.  Expected Impacts of Connected Multimodal Imaging in Precision Oncology.

Authors:  Marco D Dominietto; Enrico Capobianco
Journal:  Front Pharmacol       Date:  2016-11-29       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.